Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 532-538, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nickmilder, M. J. M.
Right arrow Articles by Lhoëst, G. J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickmilder, M. J. M.
Right arrow Articles by Lhoëst, G. J. J.
Related Collections
Right arrow Clinical Immunology
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:532-538.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Isolation and identification of a C39 demethylated metabolite of rapamycin from pig liver microsomes and evaluation of its immunosuppressive activity

Marc J. M. Nickmilder1, Dominique Latinne2, Jean-Paul De Houx2, Roger K. Verbeeck1, and Georges J. J. Lhoëst1,a

1 Department of Pharmaceutical Sciences-UCL, Pharmacokinetics and Metabolism Unit, Laboratory of Mass Spectrometry, 7246, Av. E. Mounier, B-1200 Brussels, Belgium.

2 Experimental Immunology Unit-UCL, Clos Chapelle aux Champs, 3056, B-1200 Brussels, Belgium.
a Author for correspondence. Fax 32 2 2624150;

We studied in vitro metabolism of rapamycin using pig liver microsomes. After extraction of the metabolites from the incubation medium, the crude metabolite extract was submitted to normal and subsequently to reversed-phase HPLC chromatography. We describe in the current study a metabolite of retention time 23.2 min collected from reversed-phase HPLC and identified by fast atom bombardment mass spectrometry (MS) and electrospray MS-MS as a C39 demethylated rapamycin metabolite. In vitro immunosuppressive activity of this metabolite, determined by the mixed lymphocyte reaction, was negligible compared with that of the parent compound. The decrease of in vitro immunosuppressive activity compared with the parent compound is likely to be attributed to important structural modifications of the rapamycin binding region to the FK-506 binding protein.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.